Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 20 for “"VRC01"”.

  1. Eliciting VRC01-like broadly neutralizing antibodies using IPAS-RAM vaccine strategy in VRC01-germline mice

    … antibodies from infected individuals, including VRC01, 10E8, and 4E10. These antibodies target the viral envelope glycoprotein and possess the ability to neutralize the virus. Among the viral regions of interest, gp120 has received significant attention due to its crucial role in binding to CD4 …

    iastate Repository record for Eliciting VRC01-like broadly neutralizing antibodies using IPAS-RAM vaccine strategy in VRC01-germline mice (opens in a new tab)

  2. Eliciting VRC01-class antibodies against HIV-1 through immunization

    … through vaccination, they will be protective.VRC01-class Abs are amongst the most broad and potent neutralizing and therefore desirable to elicit during vaccination. VRC01-class Abs target the CD4-binding site (CD4-BS) on the HIV-1 Env. All members of this class have high levels of somatic …

    washington Repository record for Eliciting VRC01-class antibodies against HIV-1 through immunization (opens in a new tab)

  3. Identification of novel viral mutations in HIV-1 subtype C conferring resistance to the broadly neutralizing antibody, VRC01

    … studies, which showed that the CD4bs antibody VRC01 effectively protected against the acquisition of HIV-1 in only 30% of virus isolates that were highly sensitive to VRC01, with no protection against resistant isolates. One of the challenges in using VRC01 for passive immunization is …

    nwu-za Repository record for Identification of novel viral mutations in HIV-1 subtype C conferring resistance to the broadly neutralizing antibody, VRC01 (opens in a new tab)

  4. HIGH-RESOLUTION ANALYSIS OF HIV ENVELOPE-SPECIFIC ANTIBODY RESPONSES TO ACCELERATE RATIONAL IMMUNOGEN DESIGN

    … sequence of a virus strain isolated from bNAb VRC01 donor, which can engage the VRC01 germline precursor in vitro. Sequential prime-boost immunizations in a VRC01-germline immunoglobulin (Ig) encoding genes knock-in mouse model with the designed immunogens induced focused VRC01-like serum …

    maryland Repository record for HIGH-RESOLUTION ANALYSIS OF HIV ENVELOPE-SPECIFIC ANTIBODY RESPONSES TO ACCELERATE RATIONAL IMMUNOGEN DESIGN (opens in a new tab)

  5. Humanized Mouse with a Diverse Polyclonal B Cell Repertoire as a Model for Neutralizing Antibody Responses against EBV and HIV

    … of these humanized mice as a surrogate to model VRC01-class B cell responses, a rare class of HIV broadly neutralizing antibodies that target the CD4 binding site on HIV envelope. I utilized high-throughput sequencing to identify the presence of these rare potentially protective B cells in …

    washington Repository record for Humanized Mouse with a Diverse Polyclonal B Cell Repertoire as a Model for Neutralizing Antibody Responses against EBV and HIV (opens in a new tab)

  6. Evaluating the Effects of Broadly Neutralizing Antibodies on HIV-1 Reservoirs through Proviral Landscape Analyses

    … to assess the effect of the CD4 binding bNAb, VRC01, in a clinical trial of infants initiating ART in the IMPAACT 2008. Methods: The near full-length single genome sequencing assay (nFLS) was optimized to efficiently obtain proviral sequences from pediatric samples. A series of bioinformatic …

    jhu Repository record for Evaluating the Effects of Broadly Neutralizing Antibodies on HIV-1 Reservoirs through Proviral Landscape Analyses (opens in a new tab) Embargoed until 2027-05-01

  7. Rebound Relationships: An Investigation Of Hiv-1 Rebound Dynamics And Host Immune Responses During Analytical Treatment Interruption

    … of the broadly neutralizing antibody VRC01. Our data, consistent with previous studies, demonstrated that viral rebound occurs within four weeks of ATI and is established by multiple latently infected cells in the majority of HIV-infected participants. Analyses of plasma containing …

    penn Repository record for Rebound Relationships: An Investigation Of Hiv-1 Rebound Dynamics And Host Immune Responses During Analytical Treatment Interruption (opens in a new tab)

  8. Exploring Novel B-cell Specific Immunomodulatory Adjuvants and Future Implications for HIV Vaccines

    … to activate B cells expressing a potent bNAb, VRC01 and its germline precursor (gVRC01). We hypothesized that presentation of BG505, together with a CD19 targeting antibody, a key B cell coreceptor which enhances BCR signaling, on protein nanoparticles would enhance activation of gVRC01-BCR. We …

    toronto-retro Repository record for Exploring Novel B-cell Specific Immunomodulatory Adjuvants and Future Implications for HIV Vaccines (opens in a new tab)

  9. The Activity of Breast Milk and Monoclonal HIV-specific Antibodies in Mother-to-Child Transmission

    … monoclonal antibodies (mAbs) (NIH45-46w, VRC01, PGT128, PGT121, PG9 PGT145 and b12). Maternal and infant variants did not differ in their neutralization sensitivity to these mAbs and neither did variants from transmitting versus those from non-transmitting women. However, subtype A viruses …

    washington Repository record for The Activity of Breast Milk and Monoclonal HIV-specific Antibodies in Mother-to-Child Transmission (opens in a new tab)

  10. Manipulation of the Nicotiana benthamiana immune response to Agrobacterium tumefaciens to improve plat molecular farming

    … of a recombinantly expressed IgG antibody, VRC01. However, when co-expressed in an industrial scale agroinfiltration, the most promising effector did not increase final yields of VRC01 produced. We then used the ‘Traffic Light Screen’ to assess the impacts of inhibiting plant defence …

    oxford Repository record for Manipulation of the Nicotiana benthamiana immune response to Agrobacterium tumefaciens to improve plat molecular farming (opens in a new tab)

  11. Pharmacokinetic and pharmacodynamic evaluation of HIV-1 pre-exposure prophylaxis candidates in humanized mice

    … In another PD study, protective efficacy of bnAb VRC01 was examined against mucosal transmission of HIV-1 in the form of topical PrEP. The VRC01 gel (1 mg/ml) conferred protection in 77.7% (7/9) animals, while the combination of b12, 4E10, 2F5 and 2G12 bnAb which target different epitopes on the …

    colostate Repository record for Pharmacokinetic and pharmacodynamic evaluation of HIV-1 pre-exposure prophylaxis candidates in humanized mice (opens in a new tab)

  12. Designing Multi-Epitope Supramolecular Nanofiber Vaccines for Autoimmunity and Infectious Disease

    … of a peptide epitope for activation of the VRC01 Ramos B cell line. This cell line was described in 2017 and contains a B-cell Receptor (BCR) that is identical to the anti-HIV broadly-neutralizing monoclonal antibody VRC01. Other groups had previously published epitope mimicking peptide …

    duke Repository record for Designing Multi-Epitope Supramolecular Nanofiber Vaccines for Autoimmunity and Infectious Disease (opens in a new tab)

  13. A Novel Gene Therapy Approach Based on Secreted Antiviral Proteins for the Control of HIV Replication

    … of several primary isolates more potently than VRC01, sCD4, or sCD4-scFv17b. Taken together, we have shown that human cells can be engineered to secrete HIV inhibitors. Furthermore, our results highlight the benefit of combining inhibitors that target receptor-binding and membrane fusion.

    toronto-retro Repository record for A Novel Gene Therapy Approach Based on Secreted Antiviral Proteins for the Control of HIV Replication (opens in a new tab)

  14. Processing of recombinant human IgGs in agroinfiltrated leaves of Nicotiana benthamiana

    … COVA2-15, anti-EBOV 2G4 and anti-HIV VRC01. <em>In vitro</em> incubation of IgGs with apoplastic fluids demonstrated that subtilase SBT5.2 is the sole protease responsible for 2F5 cleavage. Moreover, we found that different antibodies exhibit varying levels of susceptibility to …

    oxford Repository record for Processing of recombinant human IgGs in agroinfiltrated leaves of Nicotiana benthamiana (opens in a new tab)

  15. Identification, molecular cloning and characterization of transmitted/founder HIV-1 subtype A, D and AD viruses and envelope glycoproteins

    … respect to sensitivity to monoclonal antibodies VRC01, PG9 and PG16 and polyclonal subtype C anti-HIV IgG (p<0.05 for each). Surprisingly, we found that T/F HIV-1 subtype B and C viruses replicated poorly in primary human macrophages. Because clinical studies have reported an association between …

    uab Repository record for Identification, molecular cloning and characterization of transmitted/founder HIV-1 subtype A, D and AD viruses and envelope glycoproteins (opens in a new tab)

  16. Identifying Cellular and Molecular Mechanisms of Amphiphile Protein Subunit Vaccines that Drive B Cell Activation and Immunity

    … calcium flux assays using a germline-reverted VRC01 (glVRC01) B cell line, alongside in vivo lymphatic trafficking and immunogenicity studies in mice, I compared amphiphile-conjugated proteins against soluble and micellar formats. While both amphiphile ‘painted’ cells and micelles present …

    umn Repository record for Identifying Cellular and Molecular Mechanisms of Amphiphile Protein Subunit Vaccines that Drive B Cell Activation and Immunity (opens in a new tab)

  17. Immune defense of the female lower reproductive tract and the use of monoclonal antibody-based topical microbicide films to protect against HIV infection

    … MB66, is a film containing two antibodies: VRC01 (anti-HIV) and HSV-8 (anti HSV-2). We hypothesize that the new MB66 topical microbicide film will provide protection against these sexually transmitted viruses without inducing inflammation in the vaginal epithelium, and will prove to be a …

    bu Repository record for Immune defense of the female lower reproductive tract and the use of monoclonal antibody-based topical microbicide films to protect against HIV infection (opens in a new tab)

  18. Innate immune responses of vaginal epithelium and activity of monoclonal antibody-based microbicide in the presence of lactic acid, a lactobacillus metabolite

    … as low as pH 3.5 did not affect the ability of VRC01, to prevent HIV infection. We found that LA, at concentrations present in vaginal secretions of normal women, inhibited the inflammatory response to a TLR agonist, possibly due to upregulated Il-1RA synthesis. In addition, the functionality of …

    bu Repository record for Innate immune responses of vaginal epithelium and activity of monoclonal antibody-based microbicide in the presence of lactic acid, a lactobacillus metabolite (opens in a new tab)

  19. The screening of neutralising antibodies against a resistant HIV-1 strain to identify novel epitopes

    … resistant to the extremely broad and potent mAb VRC01 (anti-CD4-bs). QH343.A10 was also found to be resistant to neutralisation by soluble CD4 (sCD4). This made the virus attractive to use in our system as antibodies that recognise QH343.A10 in the same manner as these mAbs are also unlikely to …

    cape-town Repository record for The screening of neutralising antibodies against a resistant HIV-1 strain to identify novel epitopes (opens in a new tab)

  20. Running the Gamut: From Structural Biology to HIV-1 Vaccine Design

    Transmembrane proteins are major drug targets in bacteria, viruses, and humans. Utilizing a combination of single-particle electron microscopy, mass spectrometry, and numerous other biophysical and biochemical techniques, my thesis work has elucidated the structures and mechanisms of multiple …

    washington Repository record for Running the Gamut: From Structural Biology to HIV-1 Vaccine Design (opens in a new tab)